Participate in Research

Castration-Resistant Prostate Cancer Study
Protocol: STUDY00006886
Full Title
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
The University at Buffalo (UB) Department of Medicine is looking for adults who have prostate cancer that has spread beyond the prostate and continues to grow despite being treated with at least 2 different types of treatment that are approved and known to be effective against prostate cancer.

Since this is the first ongoing study of EPI-7386 in humans, there is limited information about how it affects people or what dose should be used. Therefore, the main purpose of this study is to assess the safety (side effects) of EPI-7386 and to find a dose that can be given without unacceptable side effects.

It is not possible to predict exactly how long your study participation will last, because the length of the study treatment period cannot be predicted for an individual participant.
Compensation: No
Adults 18 years or older Have been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) Must have progressed on at least 2 prior approved systemic therapies for mCRPC
Age Group: Adults
Principal Investigator: ROBERTO PILI Open Study
Ashlee Lang
+1 716-859-8519
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions